Skip to main content

Market Overview

Mid-Morning Market Update: Markets Mostly Lower; Isle of Capri Casinos Profit Beats Views


Following the market opening Tuesday, the Dow traded down 0.25 percent to 17,688.07 while the NASDAQ climbed 0.07 percent to 4,852.02. The S&P also fell, dropping 0.12 percent to 2,076.48.

Leading and Lagging Sectors

On Tuesday, technology shares rose by 0.21 percent. Top gainers in the sector included Preformed Line Products Company (NASDAQ: PLPC) and Skullcandy Inc (NASDAQ: SKUL).

In trading on Tuesday, basic materials shares declined by 0.35 percent. Meanwhile, top losers in the sector included Endeavour Silver Corp (NYSE: EXK), down 2 percent, and Eldorado Gold Corp (USA) (NYSE: EGO), down 3 percent.

Top Headline

Isle of Capri Casinos (NASDAQ: ISLE) reported better-than-expected earnings for its fourth quarter on Tuesday.

The company posted adjusted earnings of $0.62 per share on revenue of $264.9 million. However, analysts were expecting earnings of 0.54 per share on revenue of $266.8 million.

Equities Trading UP

Leading Brands, Inc (USA) (NASDAQ: LBIX) shares shot up 110 percent to $3.01 following Q1 results. Leading Brands reported Q1 earnings of $0.10 per share on revenue of $3.033 million.

Shares of Achaogen Inc (NASDAQ: AKAO) got a boost, shooting up 15 percent to $4.34. Wedbush upgraded Achaogen to Outperform, increasing the price target from $7.00 to $10.00.

Yingli Green Energy Holding Co Ltd (ADR) (NYSE: YGE) shares were also up, gaining 15 percent to $4.90 following earnings results. Yingli Green posted Q1 earnings of $0.60 per ADS on revenue of $364.6 million.

Equities Trading DOWN

Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares dropped 69 percent to $1.38. Infinity announced plans to cut 21 percent of the workforce. The company also reported that DYNAMO Phase 2 monotherapy study evaluating the efficacy and safety of duvelisib met its primary endpoint.

Shares of Mesoblast limited (ADR) (NASDAQ: MESO) were down 39 percent to $4.30 as the company issued an update on global heart failure program. The company reported that it has regained rights to cardiovascular field for cell therapy platform.

Revance Therapeutics Inc (NASDAQ: RVNC) was down, falling around 25 percent to $13.75 as the company reported that its REALISE 1 Phase 3 trial of DaxibotulinumtoxinA Topical Gel (RT001) to treat patients with moderate to severe lateral canthal lines (crow's feet) had failed to meet co-primary and other endpoints.


In commodity news, oil traded down 0.94 percent to $48.61 while gold traded up 0.85 percent to $1,286.70.

Silver traded up 0.58 percent Tuesday to $17.43, while copper rose 1.03 percent to $2.05.


European shares were lower today. The eurozone's STOXX 600 fell 1.84 percent, the Spanish Ibex Index dropped 2.20 percent, while Italy's FTSE MIB Index slipped 2.91 percent. Meanwhile the German DAX declined 1.80 percent, and the French CAC 40 fell 1.85 percent, while U.K. shares fell 1.16 percent.


The NFIB small business optimism index increased 0.2 point to 93.8 in May.

U.S. retail sales rose 0.50 percent in May, versus economists' expectations for a 0.30 percent growth.

U.S. import prices gained 1.4 percent in May, while rose 1.1 percent in the same month.

The Johnson Redbook Retail Sales Index declined 1 percent during the first two weeks of June versus May.

U.S. business inventories rose 0.10 percent for April, versus economists' expectations for a 0.20 percent growth.

The Treasury is set to auction 4-week bills.

The Federal Open Market Committee begins two-day policy meeting today.


Related Articles (PLPC + SKUL)

View Comments and Join the Discussion!

Posted-In: Earnings News Eurozone Commodities Global Intraday Update Markets Movers

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at